6 results about "Clostridial toxin" patented technology

The invention relates to the technical field of biological medicine, in particular to a composition for blocking formation of phage treatment tolerance and application of the composition. The composition comprises a folium ilicis purpurea ethyl acetate extraction active component and a clostridium perfringens specific bacteriophage, the folium ilicis purpurea ethyl acetate extraction active component is prepared from the following components in percentage by mass: 8 to 15 percent of protocatechuic acid and 5 to 10 percent of ethyl gallate, and the mass ratio of the protocatechuic acid to the ethyl gallate is (1.5 to 1) to (2.5 to 1); the clostridium perfringens specific bacteriophage is a virulent bacteriophage capable of specifically cracking a clostridium perfringens NetB toxin positive strain. According to the invention, the shallow thought that the existing compounding technology only pursues synergistic sterilization is subverted, and a deep synergistic mode of bacteriophage splitting attack and folium ilicis purpurea component disintegration bacterial defense program is proposed and verified for the first time. And the formation of tolerance is fundamentally blocked, so that a more thorough and more lasting treatment effect is realized, and the comprehensive production performance of animals is accidentally and greatly improved on the basis of the treatment effect.

Antibody-based binding agents derived from human and camelid immunoglobulins are described, as well as strains of yeast engineered to secrete the binding agents, and methods of treating and preventing Clostridium difficile infections using the engineered strains of yeast. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and / or toxin B and in some cases exhibit toxin neutralizing activity. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.

The invention discloses a clostridium perfringens alpha toxin monoclonal antibody, a hybridoma cell strain and application. The monoclonal antibody is generated by a hybridoma cell strain CPA-3B8 with the preservation number of CCTCC NO: C2025127, the sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO. 1, and the sequence of a light chain variable region of the monoclonal antibody is as shown in SEQ ID NO. 2. The invention also discloses a competitive ELISA method established by using the monoclonal antibody, the method optimizes key parameters such as antigen coating concentration, closing conditions, competition time and the like, and determines a positive critical value (PI is greater than or equal to 38.56%) and a negative critical value (PI is less than or equal to 30.73%). The method has the advantages of high sensitivity, strong specificity, good repeatability and the like, can be used for detecting the clostridium perfringens alpha toxin antibody in animal serum, and provides an effective tool for vaccine immune effect evaluation and disease diagnosis.

In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and / or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and / or toxin B is sustained.